Biotech News
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
RIGL (RIGL) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.
The source domain is rigl.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.
The original release is available below in a new tab so readers can continue into the full source when needed.